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Abstract
Aims: The mechanisms by which a ‘Mediterranean diet’ reduces cardiovascular disease (CVD) burden remain poorly
understood. Lycopene is a potent antioxidant found in such diets with evidence suggesting beneficial effects. We wished to
investigate the effects of lycopene on the vasculature in CVD patients and separately, in healthy volunteers (HV).
Methods and Results: We randomised 36 statin treated CVD patients and 36 healthy volunteers in a 2:1 treatment
allocation ratio to either 7 mg lycopene or placebo daily for 2 months in a double-blind trial. Forearm responses to intra-
arterial infusions of acetylcholine (endothelium-dependent vasodilatation; EDV), sodium nitroprusside (endothelium-
independent vasodilatation; EIDV), and NG-monomethyl-L-arginine (basal nitric oxide (NO) synthase activity) were measured
using venous plethysmography. A range of vascular and biochemical secondary endpoints were also explored. EDV in CVD
patients post-lycopene improved by 53% (95% CI: +9% to +93%, P= 0.03 vs. placebo) without changes to EIDV, or basal NO
responses. HVs did not show changes in EDV after lycopene treatment. Blood pressure, arterial stiffness, lipids and hsCRP
levels were unchanged for lycopene vs. placebo treatment groups in the CVD arm as well as the HV arm. At baseline, CVD
patients had impaired EDV compared with HV (30% lower; 95% CI:245% to210%, P= 0.008), despite lower LDL cholesterol
(1.2 mmol/L lower, 95% CI: 21.6 to 20.9 mmol/L, P,0.001). Post-therapy EDV responses for lycopene-treated CVD patients
were similar to HVs at baseline (2% lower, 95% CI: 230% to +30%, P= 0.85), also suggesting lycopene improved endothelial
function.
Conclusions: Lycopene supplementation improves endothelial function in CVD patients on optimal secondary prevention,
but not in HVs.
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Introduction
The incidence of cardiovascular disease (CVD) varies worldwide
but is notably reduced in southern Europe where a ‘Mediterra-
nean diet’ predominates; consisting mainly of a larger consump-
tion of fruit, vegetables and olive oil [1,2]. Recent primary
prevention interventional dietary trials, and a large observational
analysis demonstrate that this diet reduces the incidence of CVD
events in asymptomatic patients at high cardiovascular risk, and
also, in conjunction with effective secondary prevention medica-
tion, is associated with a lower incidence of recurrent CVD events
[3–5]. The mechanisms underlying this effect are unclear but may
be partly due to a high antioxidant component of the diet.
Lycopene is a lipophilic, active carotenoid component of
tomatoes giving them their distinctive red colour. It is a potent
antioxidant with a singlet-oxygen quenching ability twice that of b-
carotene and ten times that of Vitamin E due to its structure
(Figure S1) [6]. There is an inverse association between lycopene
levels and surrogate endpoints of cardiovascular disease
in observational studies, and in-vitro studies have suggested
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anti-atherogenic mechanisms of action [7–12]. Interventional
studies investigating in-vivo effects on vascular function have been
limited by utilisation of unstandardized food based interventions
involving consumption of large volumes of tomato products (e.g.
juice or paste) or by the use of heterogeneous tomato extracts
containing mixtures of carotenoids [13–19].
The ‘residual risk’ of developing further events seen in some
CVD patients, despite aggressive lipid lowering with statins and
other drugs, may be partly explained by persistent underlying
impaired endothelial function [20–22]. Nitric oxide (NO) acts as a
central signal transduction pathway in the endothelium, regulating
haemostasis and platelet aggregation as well as vascular tone
[20,23,24]. Diminished NO levels are seen in early in atheroscle-
rosis [20]. NO bioavailability can be assessed in-vivo by venous
occlusion plethysmography, using intra-arterial infusion of acetyl-
choline, which prospectively predicts risks of developing CVD
related events and improves risk classification beyond the
Framingham scores [25,26].
We hypothesised that lycopene would improve endothelial
function in patients with pre-existing CVD, and separately, in
healthy volunteers (HV) also. In order to determine lycopene’s
mechanistic effects on vascular physiology, we used a commer-
cially available oral lycopene preparation with high bioavailability
(Ateronon, Cambridge Theranostics, UK). Endothelial function
was determined using forearm vascular responses to acetylcholine
(ACh; stimulating NO production). Secondary outcomes included
forearm responses to sodium nitroprusside (SNP; measuring
vascular smooth muscle sensitivity) and NG-monomethyl-L-argi-
nine (L-NMMA; measuring basal NO synthase activity) infusion,
arterial stiffness, blood pressure, serum lycopene concentrations,
and safety and tolerability parameters. A number of exploratory
end-points including oxidised low-density lipoprotein (ox-LDL),
high sensitivity C-reactive protein (hsCRP), cytokine profile,
urinary isoprostanes and plasma nitrotyrosine levels (markers of
oxidative stress) were measured to explore postulated mechanisms.
Methods
Study Design and Ethics Statement
This was a prospective, randomised, double-blind, placebo-
controlled, parallel group study comparing lycopene 7 mg with
placebo (Ateronon and matching placebo, Cambridge Theranos-
tics, Cambridge, UK) in two separate arms, namely CVD patients
and HVs (Figure 1). The study was conducted in the Clinical
Pharmacology Unit, University of Cambridge, United Kingdom.
The protocol received a favourable opinion from the Hertford-
shire Research Ethics Committee, and was deemed not to be a
clinical trial of an investigational medical product by the
Medicines and Healthcare products Regulatory Agency (MHRA).
As the trial was a physiological study, there was no requirement for
it to be registered on a clinical trials database based on UK
regulations in 2009. Nevertheless, the trial was registered at
clinicaltrials.gov (NCT01100385) approximately two weeks after
commencement, and complied with the Declaration of Helsinki
with full written informed consent from all subjects.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Study Populations
There were two separate, yet parallel arms to our study –
patients with CVD and separately, HVs.
In our CVD arm, patients aged 40–80 with stable cardiovas-
cular disease (defined as any one or more of previous myocardial
infarction, coronary stent, angina diagnosed on angiography/
other imaging modality or exercise/stress testing, transient
ischaemic attack or stroke disease, or peripheral vascular disease)
were recruited if they were on stable statin therapy for at least two
months. Exclusion criteria were uncontrolled hypertension of .
180/110 mmHg, a Body Mass Index (BMI) .35 kg/m2, preg-
nancy, or active malignancy. CVD patients were asked to continue
on their regular medications, without changes, throughout the trial
period.
Healthy volunteers aged 30–80 with no smoking history were
eligible for a separate, parallel arm of the study. Subjects in this
arm were also required to be normotensive, non-diabetic, not
pregnant, and on no regular medication including the oral
contraceptive pill, nor statins or other vasoactive drugs including
Non-Steroidal Anti-Inflammatories (NSAIDs). Volunteers with a
BMI .32 or ,18 were excluded as were those with active renal,
respiratory, neurological, or oncological disease.
We did not attempt to prospectively stratify each arm to the
other since these were parallel studies.
Interventions
Lycopene 7 mg and placebo (Ateronon and matching placebo
in shape, size and colour) were donated by Cambridge
Theranostics (Cambridge, United Kingdom). Drug and placebo
were randomised unequally (2:1 ratio) by the independent
manufacturer of Ateronon (Indena, Milan, Italy). Subjects in each
study arm (CVD or HV) were sequentially allocated from a
computer-generated randomisation to receive either lycopene
7 mg or placebo once daily for two months. Study personnel and
subjects were blinded to treatment assignment for the duration of
the study and final analysis of data. Subjects were advised to
maintain their regular diet without restrictions or significant
changes to replicate ‘real world’ conditions, more so since we were
measuring lycopene levels at study start and end in all subjects.
Forearm Blood Flow
Forearm blood flow (FBF) was measured by venous occlusion
plethysmography (Hokanson Inc, Bellevue, USA) as previously
described [25] using the protocol illustrated in Figure 2. Wrist
circulation was excluded by inflating wrist cuffs above the systolic
blood pressure. Upper arm cuffs were intermittently inflated (to
40 mm Hg) and deflated at short intervals over 3 minutes to
measure FBF with mercury-in-silastic gauges. The dominant arm
was established, where possible, as a control arm without
cannulation or test infusions. In contrast, acetylcholine (ACh;
Novartis Pharmaceuticals, Basel, Switzerland), sodium nitroprus-
side (SNP; Nitroprussiat FIDES, Madrid, Spain), and NG-
monomethyl-L-arginine (L-NMMA; Bachem Distribution Services
GmBH, Weil am Rhein, Germany) were infused in a fixed order
into the brachial artery of the non-dominant (test) arm via a 27-
gauge needle inserted under local anaesthesia. All drugs were
prepared aseptically and diluted in sterile saline (0.9% Maco
Pharma, London, United Kingdom). All infusions were performed
at a rate of 1 mL/min. Saline was infused to establish a baseline
before infusion of each challenge agent of acetylcholine (7.5 mg/
min; 15 mg/min), SNP (3 mg/min; 10 mg/min), and L-NMMA
(2 mg/min; 4 mg/min) (Figure 2). Each challenge agent was
infused at 2 doses, and each dose was infused for 6 minutes. FBF
was recorded in both arms over the last 3 minutes of each infusion.
The primary end-point for each arm of our study was change in
endothelium-dependent vasodilatation (EDV; response to 15 mg/
min ACh) from baseline, comparing lycopene with placebo
treatment allocation groups within each arm. This was chosen
based on previous data suggesting that only responses to higher
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doses of ACh correlated with clinical outcomes [26]. Secondary
end-points were endothelium-independent vasodilatation (EIDV;
response to 10 mg/min SNP) and vasoconstrictor responses to
4 mmol/min L-NMMA.
Haemodynamics (blood pressure and heart rate) were measured
in the brachial artery of the dominant, non-infused arm at baseline
and at the end of the infusion period for each challenge agent with
a validated oscillometric machine (Omron HEM-705CP, Omron
Corp, Kyoto, Japan) [27]. The measurements were taken after 24
minutes and then at the end of each challenge period (Figure 2).
Measurements were taken pre-dose on day 1 (baseline), and
post-dose on day 56 for all subjects. All measurements were
conducted in the morning in a quiet, temperature-controlled
(22uC to 24uC) clinical laboratory. Subjects fasted overnight and
abstained from alcohol and caffeine-containing drinks for 24 hours
before measurement. CVD patients were asked to omit their
medications on the morning of the vascular studies. At the end of
the whole study, all the FBF data sets underwent quality
assessment by two independent blinded parties where any non-
evaluable and incomplete data sets were removed from the
database before subsequent unblinding and statistical analysis.
Arterial Stiffness
Measurements of arterial stiffness were conducted as previously
described [28]. After 15 minutes of supine rest, peripheral blood
pressure was recorded in the brachial artery (OMRON-705CP;
Omron Corp, Kyoto, Japan). Aortic (carotid to femoral) pulse
wave velocity (PWV) was measured using a high-fidelity micro-
manometer (SPC-301; Millar Instruments, Houston, USA), and a
corresponding central waveform using a validated transfer
function (Sphygmocor; AtCor Medical, Sydney, Australia). Aug-
mentation index (AIx) and heart rate were determined with the
integrated software. All measurements were made in duplicate and
mean values used in the subsequent analyses.
Blood Pressure
Subjects were asked to record resting, seated home blood
pressure (BP) readings both morning and evening using a validated
device for any seven days in the 2 weeks prior to vascular
assessments. Three readings were made each time, with the
average of the final two recorded in a diary and used for analysis.
Clinic peripheral BP measurements were taken prior to the arterial
stiffness measurements and central BP measurements were
estimated non-invasively by the validated Sphygmocor apparatus
[29,30].
Laboratory Assessments
Blood samples were taken for routine haematology and clinical
chemistry tests on day 1 and 56. Samples were also taken for lipid
profile, high sensitivity C-reactive protein (hsCRP), oxidised low-
density lipoprotein (ox-LDL, Mercodia, Uppsala, Sweden), serum
lycopene levels (high-performance liquid chromatography with
ultraviolet detection) as well as other exploratory biomarkers.
Urine samples were stored immediately at 280uC for urinary
isoprostanes (Cell BioLabs Inc., San Diego, USA).
Safety Assessments
A detailed collection of safety data, including bloods, adverse
events and serious adverse events, were monitored throughout the
study in accordance with Good Clinical Practice. A complete set of
Figure 2. Schematic of forearm blood flow protocol. ACh: Acetylcholine; SNP: Sodium Nitroprusside; L-NMMA: NG-monomethyl-L-arginine; H:
Haemodynamic measurements.
doi:10.1371/journal.pone.0099070.g002
Figure 1. Flow diagram of subjects through the study. The safety population consisted of anyone who received at least 1 dose of study drug.
*Reasons for failure to enrol included not meeting inclusion criteria, an inability to attend laboratory for assessments within the appropriate
timeframe, patient withdrawal, inability to lie flat for a period of time for the studies, or an inability to cannulate the brachial artery. **Quality control
evaluation done by two independent parties. Reasons for non-evaluable data and consequent exclusion from final forearm blood flow (FBF) analysis
(before unblinding and statistical analysis) included incomplete data sets, non-evaluable sets, and FBF procedure variation.
doi:10.1371/journal.pone.0099070.g001
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safety observations, including heart rate, blood pressure, and 12-
lead ECGs, were recorded at screening, day 1 and 56.
Statistical Methods
For sample size calculation, the CVD and HV arms were
treated as individual studies. Sample size calculation was based on
the variability of primary endpoint - change in infused arm
forearm responses following 15 mg/min ACh from the preceding
saline baseline. Based on a standard deviation of 25% in change
from baseline FBF [31], it was estimated that for each arm of our
study (i.e. CVD and HV) a sample size of 30 subjects in an
unequal 2:1 randomisation (drug: placebo) would provide 90%
power to detect a clinically relevant 20% absolute difference [26]
between the groups of change in ACh responses from baseline
with a two-tailed alpha level of significance of 5%. The primary
endpoint was evaluated separately for CVD and HV arms. An
unequal randomisation method was employed for feasibility
purposes of conducting such a large study within one academic
centre with this robust but minimally invasive technique. We
recruited 36 subjects each for the CVD and HV arms (total n = 72
overall) to account for potential dropouts and unevaluable data.
Data were analysed on an intention-to-treat basis on the full
analysis set of an intention-to-treat protocol as set out by the ICH
E9 guidelines on statistical principles for clinical trials [32].
Absolute infused arm FBF values were analysed by infusion
agents using a repeat measures analysis of variance model
(ANOVA), with a term for drug/placebo, visit day, infusion dose
within day, and interaction of treatment and dose within day, in
which the preceding saline baseline was treated as infusion dose
zero and the higher dose of challenge agent as infusion dose 1.
Greenhouse – Geisser corrected probability values were used if
Mauchly’s test revealed a violation of sphericity. Blood pressures
were averaged from subject diary cards and mean values
compared using repeat measures ANOVA with a term for drug/
placebo, visit day, and interaction of treatment and day. Home
blood pressure variability was calculated by taking the standard
deviation of the readings from the subject diary cards prior to each
visit and analysing them using repeat measures ANOVA with a
term for drug/placebo, visit day, and interaction of treatment and
day. Changes in arterial stiffness and concentrations of biomarkers
were analysed using analysis of covariance (ANCOVA) with
baseline value at day 1 as a covariate and treatment group as fixed
factors [33].
Post-hoc comparisons at single time points of baseline physio-
logical and biochemical parameters between healthy volunteers
and CVD patients were performed using unpaired, 2-tailed
Student t tests, or using x2 tests for categorical variables. As a
single dose of lycopene was used, variations in serum lycopene
levels due to dietary intake in addition to the intervention
(lycopene or placebo) were compared to the primary endpoint in a
post-hoc analysis to demonstrate dose-response characteristics and
to examine any effects of extraneous dietary changes. Correlations
between change in lycopene levels and change in FBF responses
were investigated by calculating the Pearson product moment
correlation coefficient. Adverse event rate was calculated as
number of subjects experiencing adverse events in lycopene or
placebo groups divided by total numbers of subjects in lycopene or
placebo groups, expressed as a percentage, with comparisons
made using a x2 test. For all analyses, a probability of ,0.05 was
considered significant. Statistical analyses were performed using
SPSS version 20 (IBM, Somers, New York, USA).
Results
The study protocol was approved in April 2010 and the final
subject completed the study in May 2012 (Figure 1).
Baseline Demographics
The demographics of the lycopene and placebo treatment
allocation groups for the separate CVD and HV arms are
described in Table 1. In general, lycopene and placebo treatment
groups were well matched across major variables in both CVD
and HV arms. There were slightly more women in the HV arm
compared to the CVD arm, reflecting the increased prevalence of
cardiovascular disease in men. All CVD patients were on stable
doses of statins (mean equivalent simvastatin dose of 40 mg), with
a high proportion on other secondary prevention medication such
as anti-platelets and anti-hypertensives (Table 1).
Table 1. Baseline Demographics of CVD Patients and HV arms.
CVD Patients HVs
Lycopene Placebo Lycopene Placebo
N 24 12 24 12
Age – years [mean (SD)] 67 (6) 68 (5) 61 (13) 68 (5)
Sex - M:F 23:1 10:2 15:9 10:2
BMI – kg/m2 [mean (SD)] 28.6 (3.3) 28.4 (4.0) 25.2 (2.8) 26.7 (3.6)
Current Smoker [n (%)] 2 (8) 0 (0) 0 (0) 0 (0)
Ex-Smoker [n (%)] 18 (75) 6 (50) 9 (38) 7 (58)
EtOH units/week [mean (SD)] 12.9 (11.3) 9.2 (9.1) 11.8 (12.9) 7.6 (7.5)
Statins [n (%)] 24 (100) 12 (100) 0 (0) 0 (0)
ACE-I/ARB [n (%)] 22 (92) 8 (67) 0 (0) 0 (0)
b-blockers [n (%)] 13 (54) 5 (42) 0 (0) 0 (0)
Antiplatelet [n (%)] 24 (100) 12 (100) 1 (4) 0 (0)
Mean duration of dosing – days [mean (SD)] 57 (4) 56 (6) 60 (9) 61 (6)
Data are presented as mean (standard deviation - SD) or numbers (%). ACE-I: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin Receptor Blocker; CVD:
cardiovascular disease; EtOH: Alcohol; HV: healthy volunteer.
doi:10.1371/journal.pone.0099070.t001
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Figure 3. Changes in Forearm Blood Flow. Infused arm forearm blood flow values in cardiovascular disease patients (A–C) and healthy
volunteers (D–F) before dose on day 1 (broken lines) and after dose on day 56 (solid lines) for lycopene (red lines) and placebo (blue lines) in response
to acetylcholine (ACh; graphs A and C); sodium nitroprusside (SNP; graphs B and D), and NG-monomethyl-L-arginine (L-NMMA; graphs C and F)
Vascular Effects of Lycopene
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Forearm Blood Flow
CVD patients randomised to lycopene treatment demonstrated
improved EDV (63% higher, 95% CI: +19% to +108%,
P= 0.008). No changes were noted in EIDV or basal NO synthase
activity. No changes were observed over the treatment period in
the placebo group (EDV: 7% lower, 95% CI: 241% to +56%,
P=0.8); (Figure 3; A, B, C). After placebo correction, EDV was
improved significantly by 53% (95% CI: +9% to +93%, P=0.03)
in the lycopene treated CVD group. No significant differences
were seen between lycopene-treated and placebo groups in
forearm responses to SNP or L-NMMA (Table S1). There were
no changes in the control arm FBF values during the challenge
agent infusions.
No significant changes were noted in FBF responses to ACh,
SNP, or L-NMMA in the HV cohort between lycopene and
placebo (Figure 3; D, E, F and Table S2). There were no
changes in the control arm FBF values during the challenge agent
infusions.
At baseline, CVD patients had significantly impaired
EDV compared with HVs (30% lower, 95% confidence interval
[CI]: 250% to 28%, P=0.008). No differences were seen in
baseline EIDV or vasoconstrictor responses to L-NMMA. In a
post-hoc analysis, EDV responses post-lycopene therapy in CVD
patients approximated the EDV responses seen in HVs at baseline
(2% lower, 95% CI:230% to +30%, P=0.85), consistent with the
relative improvement in endothelial function seen in the lycopene
treated CVD arm (Figure 4). Post-lycopene EDV responses did
not differ between CVD and HVs (16% lower, 95% CI: 228% to
+60%, P= 0.47). In further post-hoc testing to demonstrate dose
response characteristics, data from all subjects in both CVD and
HV arms of the study were pooled. There was a significant positive
correlation between change in lycopene concentration and
absolute change in EDV response between visits (r = 0.29, 95%
CI: 0.05–0.49, P=0.019, Figure 5).
Arterial Stiffness
There were no changes in arterial stiffness parameters between
lycopene treated groups and placebo in CVD patients or HVs
(Tables 2 and 3). In post-hoc analysis, unsurprisingly at baseline,
CVD patients had stiffer arteries compared with HVs as measured
by aortic PWV and augmentation index (Table 4).
Blood Pressure
Lycopene treated CVD patients achieved reductions in clinic
peripheral and central diastolic blood pressure on day 56
compared to day 1 (peripheral BP 2.9 mmHg lower, 95% CI: 2
5.5 to20.2, P=0.03 and central BP 3.3 mmHg lower, 95% CI:2
6 to 20.5, P=0.02); but these changes were not significant when
compared to placebo. No other changes were observed in BP
parameters (Tables 2 and 3). In post-hoc analysis, baseline clinic
BP and central BP were higher in the CVD arm compared with
HVs (Table 4). Mean home BPs did not differ between CVD and
HVs (Table 4).
Laboratory Assessments
Lycopene-treated patients in the CVD arm showed increases in
serum lycopene compared with placebo-treated CVD patients (D
infusions. Values represent mean with standard error (SE) bars. Comparisons were made using a repeat measures ANOVA with terms for drug/
placebo, visit day, infusion dose within day, and interaction of treatment and dose within day, in which baseline saline was treated as infusion dose
zero. P-values presented are for lycopene vs. placebo overall for the higher dose challenge agent.
doi:10.1371/journal.pone.0099070.g003
Figure 4. Post-hoc analysis of infused arm FBF values in response to ACh. Forearm blood flow (FBF) values are represented as percentage
change from preceding saline baseline with standard error bars. P-values were generated from comparisons made using unpaired, 2 tailed Student t-
tests. (A) At the start of the study, patients with cardiovascular disease (CVD) in the lycopene group (broken red line) had significantly impaired
vasodilatory responses to acetylcholine (ACh; 30% lower, 95%CI:258% to23%, P=0.03) compared with healthy volunteers (HVs) at baseline (broken
blue line). (B) After treatment with lycopene, the same patients (solid red line) show no significant changes in FBF values compared with HVs at
baseline (broken blue line) (2% lower, 95% CI: 230% to +30%, P= 0.85).
doi:10.1371/journal.pone.0099070.g004
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lycopene 130680 (active) vs. 50673 mg/L (placebo), P=0.003).
Similarly, serum lycopene levels increased in the HV arm with
active treatment when compared to placebo (D lycopene 97682
(active) vs. –19677 mg/L (placebo), P,0.001). Serum lycopene
increased by a similar amount for lycopene treated subjects in both
the CVD and HV arms of our study (P=0.2). No significant
changes were noted in other parameters in any group after
lycopene treatment (Tables 2 and 3). Urinary isoprostane
readings were below the limits of assay detection in over half the
patients in both CVD and HV arms of the study and are therefore
not reported.
Safety and Compliance Assessments
Oral lycopene supplementation was safe and well tolerated.
There were no serious adverse events, with a higher minor adverse
event rate in the placebo arm than the lycopene treated arm (54%
vs. 23%, P=0.02). Frequently reported adverse events are shown
in Table S3; the most common event was gastrointestinal upset
and all were classed as mild. There were no differences between
lycopene vs. placebo groups for routine biochemical (including
liver function tests), haematological, heart rate, blood pressure, or
ECG parameters. Overall compliance, as assessed by manual pill
count on day 56, was 96% in the CVD arm and 94% in the HV
arm.
Discussion
We have demonstrated that despite optimal secondary preven-
tion medication, endothelial function is impaired in patients with
cardiovascular disease, and this is improved by oral supplemen-
Figure 5. Post-hoc correlation between serum lycopene concentrations and EDV. Relationship between absolute change in serum
lycopene concentrations and absolute change in endothelial dependent vasodilatation (EDV; forearm blood flow response to 15 mg/min
acetylcholine measured as %change from preceding saline baseline) for all trial subjects. Absolute change in serum lycopene calculated as final visit
serum lycopene minus baseline serum lycopene. Absolute change in EDV calculated as final visit EDV minus baseline EDV. r: correlation coefficient
calculated using Pearson correlation analysis.
doi:10.1371/journal.pone.0099070.g005
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tation with 7 mg lycopene, without any concomitant changes in
traditional risk factors such as BP or lipid profiles, or measures of
inflammation. In contrast, we were unable to demonstrate any
changes in endothelial function or other parameters after lycopene
treatment in HVs.
Complex dietary modifications to alter CVD risk are recognised
as being effective but difficult to implement [34]. Recent data from
patients with a prior cardiovascular event in the Prospective
Urban Rural Epidemiology (PURE) study indicate that adherence
to a healthy diet is only apparent in 39% of the 7,519 patients
studied [35]. Further, the Prevencio´n con Dieta Mediterra´nea
(PREDIMED) interventional study added to increasing evidence
of the benefits of a ‘Mediterranean’ diet including tomato
products, in addition to a diet low in saturated fat, both for
primary and secondary prevention of CVD [3–5]. The specific
mechanisms underlying benefits of a healthy diet are poorly
defined and although dietary supplements receive much attention
within the public arena, there is a paucity of well-conducted
mechanistic studies. Previous trials of vitamin C and E supple-
mentation demonstrated conflicting effects on vascular function in-
vivo [36–39], which may explain the negative outcome trials
associated with them [40].
As the most potent antioxidant known [6], there is biological
plausibility and epidemiological data [9] suggesting that lycopene
intake may be at least partly responsible for variations in
cardiovascular mortality across Europe. Previous studies investi-
gating the vascular effects of lycopene have provided difficult to
interpret evidence of its effects – using unstandardized large
volume tomato food-based modes of delivery [13,15,18,19],
combining lycopene with other antioxidants thus making inter-
pretation of the relative benefits of individual components in
healthy people unclear [16,17], or using methods of assessing
vascular function that are not known to correlate well to clinical
outcomes [17].
We opted for a pragmatic, translational study design by
selecting a population of stable patients with CVD on statins
(which are known to improve endothelial function) [31], and in
whom ‘traditional’ risk factors for CVD were clinically optimised.
No specific dietetic advice was provided to minimise intentional
variations in dietary intake, and we corroborated the benefits of
intervention by measuring and demonstrating increased serum
lycopene levels in the intervention (lycopene treated) groups. This
enabled us to establish a potential benefit for lycopene intervention
in a real world setting in addition to optimal secondary prevention
treatment for patients with CVD.
Endothelial dysfunction may explain the ‘residual risk’ of further
events seen in patients with CVD despite optimal control and
treatment of vascular risk factors [20–22]. Importantly, we
measured endothelial function using forearm plethysmography,
which is the gold-standard method of assessing vascular function,











Aortic PWV – m/s 8.6 (1.1) 8.1 (1.0) 8.6 (0.3) 8.8 (0.4) 0.2
AIx – % 28.2 (3.1) 26.4 (3.2) 28.7 (1.6) 28.8 (1.5) 0.4
Blood Pressure
Home SBP – mmHg 125 (3) 123 (3) 126 (3) 127 (3) 0.2
Home DBP – mmHg 72 (2) 71 (2) 78 (2) 78 (2) 0.1
Home SBP variability 9.1 (0.7) 9.4 (1) 9.0 (0.7) 8.3 (0.5) 0.2
Clinic SBP – mmHg 138 (3) 137 (4) 137 (3) 133 (3) 0.4
Clinic DBP – mmHg 76 (2) 77 (2) 81 (2) 78 (2) 0.3
Central SBP – mmHg 129 (4) 127 (4) 130 (3) 126 (3) 0.6
Central DBP – mmHg 77 (2) 78 (3) 82 (2) 79 (2) 0.2
Laboratory Markers
Lycopene – mg/L 128 (26) 178 (31) 146 (14) 275 (22) 0.003
LDL – mmol/L 2.41 (0.15) 2.16 (0.14) 2.41 (0.14) 2.41 (0.12) 0.1
HDL – mmol/L 1.48 (0.14) 1.47 (0.16) 1.20 (0.05) 1.17 (0.06) 0.7
hsCRP – mg/L 1.45 (0.59) 1.68 (0.60) 2.13 (0.48) 2.37 (0.58) 0.9
ox-LDL – U/L 31.9 (17.7) 31.8 (15.6) 34.8 (17.2) 36.5 (11.7) 0.3
MMP-9– ng/ml 49.8 (21.3) 44.0 (19.5) 40.3 (17.7) 53.8 (41.1) 0.1
IL-6– pg/ml 1.20 (1.05) 0.92 (0.60) 1.54 (1.31) 1.51 (0.99) 0.3
TNF-a – pg/ml 5.55 (2.95) 5.65 (2.79) 2.13 (0.48) 2.37 (0.58) 0.9
Nitrotyrosine – mM 41.1 (47.4) 112.9 (72.1) 35.0 (20.5) 112.0 (40.9) 0.7
Data are presented as mean values (standard error - SE). *P-value is for overall comparison in delta (day 56 - day 1) values across placebo and lycopene treated groups.
AIx – augmentation index; CVD: cardiovascular disease; DBP – diastolic blood pressure; HDL – high-density lipoprotein; hsCRP – high sensitivity C-reactive protein; IL –
interleukin; LDL – low-density lipoprotein; MMP-9– matrix metalloproteinase; ox-LDL – oxidised low-density lipoprotein, PWV – pulse wave velocity; SBP – systolic blood
pressure; TNF – tumour necrosis factor.
doi:10.1371/journal.pone.0099070.t002
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and provides not only mechanistic information surrounding nitric
oxide bioavailability, but is a surrogate marker for risk of
developing CVD events, and improves risk prediction when
added to existing risk scores [26]. We were able to demonstrate a
53% improvement in ACh responses post-lycopene therapy in
CVD patients (who were impaired at baseline), but not HVs. This
is comparable to the effect size seen previously with simvastatin
20 mg in untreated hypercholesterolaemic patients [31], although
a novel finding in our study was that these effects were beyond that
conferred by effective statin therapy in an atherosclerotic
population. Parallel to this, we did not demonstrate any change
in SNP responses in either arm, suggesting that this effect was
likely primarily due to an augmentation of stimulated NO
production to acetylcholine, rather than improvement in smooth
muscle sensitivity. The role of NO in maintaining elastic artery
stiffness is unclear, with newer evidence suggesting it may not have
a significant role [41,42]. We found no change in measurements of
arterial stiffness, and therefore postulate that lycopene’s effects
may be predominantly at the level of the smaller vessels, such as
resistance arteries, rather than larger vessels. However, we contend
that we are unable to exclude if a longer duration of treatment
with lycopene, or a higher dose of lycopene may have produced
more changes in arterial stiffness.
Existing data suggest lycopene supplementation leads to
reductions in BP in subsets of patients with untreated pre-
hypertension and a reduction in markers of systemic inflammation
in patients with type 2 diabetes; although there are conflicting
results in healthy subjects [13,14,17,18,43]. We did not observe
any effect of lycopene on systemic markers of inflammation
(hsCRP, cytokine profile), BP, or arterial stiffness. However, both
CVD and HV subjects had low hsCRP levels at baseline,
suggesting that they were not systemically inflamed. Moreover,
the patients with CVD were all receiving statins and had low LDL
and ox-LDL levels which may account for the lack of observed
effects on systemic inflammatory markers. We noted a small
decrease in diastolic BP in lycopene treated CVD patients that was
not significant when placebo corrected. Interestingly, a recent
large interventional dietary study of the Mediterranean diet in
patients at high risk of CVD found decreases in diastolic, but not
systolic BP [44].
We did not include any dietary restrictions in our randomised,
blinded but real world, pragmatic trial design. Nevertheless, we
have demonstrated that subjects in the lycopene group had
increased their serum lycopene levels significantly in both CVD
and HV arms of our trial, suggesting natural variations in dietary
intake were probably minimal in our randomised trial across both
lycopene and placebo groups in both arms. Whilst we accept the
limitations of a post-hoc correlation analysis combining data from
2 non-stratified arms (namely HV and CVD patients), we were
able to demonstrate a correlation between changes in serum











Aortic PWV – m/s 7.9 (0.2) 8.1 (0.4) 7.9 (0.4) 8.1 (0.5) 1.0
AIx – % 24.1 (2.9) 23.2 (2.2) 26.3 (2.6) 25.1 (2.8) 0.9
Blood Pressure
Home SBP –mmHg 121 (3) 122 (3) 121 (4) 119 (3) 0.2
Home DBP – mmHg 74 (2) 75 (3) 72 (2) 71 (2) 0.3
Home SBP variability 8.2 (0.9) 7.8 (0.7) 8.3 (0.6) 8.1 (0.7) 0.9
Clinic SBP – mmHg 127 (4) 125 (4) 126 (4) 129 (3) 0.2
Clinic DBP – mmHg 76 (2) 75 (2) 75 (2) 77 (2) 0.2
Central SBP – mmHg 120 (4) 116 (4) 116 (4) 120 (4) 0.1
Central DBP – mmHg 78 (2) 77 (3) 76 (2) 78 (2) 0.2
Laboratory Markers
Lycopene – mg/L 182 (35) 160 (29) 170 (16) 267 (18) ,0.001
LDL – mmol/L 3.89 (0.26) 3.79 (0.21) 3.51 (0.20) 3.45 (0.19) 0.8
HDL – mmol/L 1.52 (0.11) 1.56 (0.08) 1.63 (0.10) 1.68 (0.11) 0.8
hsCRP – mg/L 2.83 (1.15) 1.65 (0.42) 1.15 (0.25) 1.87 (0.39) 0.6
ox-LDL – U/L 50.5 (32.8) 48.5 (22.1) 47.9 (25.1) 46.1 (25.2) 0.9
MMP-9– ng/ml 35.4 (27.2) 36.3 (20.4) 38.6 (17.5) 41.9 (24.7) 0.7
IL-6– pg/ml 0.92 (0.87) 0.84 (0.59) 1.32 (2.86) 1.02 (1.74) 0.8
TNF-a – pg/ml 5.55 (2.88) 5.32 (2.88) 5.39 (2.23) 4.97 (2.10) 0.7
Nitrotyrosine – mM 119.3 (55.5) 145.4 (88.1) 96.1 (35.9) 118.9 (37.1) 0.8
Data are presented as mean values (standard error - SE). *P-value is for overall comparison in delta (day 56 - day 1) values across placebo and lycopene treated groups.
AIx – augmentation index; DBP – diastolic blood pressure; HDL – high-density lipoprotein; hsCRP – high sensitivity C-reactive protein; HV – healthy volunteer; IL –
interleukin; LDL – low-density lipoprotein; MMP-9– matrix metalloproteinase; ox-LDL – oxidised low-density lipoprotein, PWV – pulse wave velocity; SBP – systolic blood
pressure; TNF – tumour necrosis factor.
doi:10.1371/journal.pone.0099070.t003
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lycopene concentrations and changes in endothelium dependent
vasodilatation, irrespective of whether this increase in lycopene
was due to changes in dietary intake or treatment allocation. This
would need further exploration in a prospective manner but does
provide some additional evidence to substantiate the mechanisms
underlying trials such as the PREDIMED study. Our baseline
serum lycopene levels were higher than those found in observa-
tional studies from Finland linking lycopene levels to risk of CVD
[10], which the authors attribute to a lower dietary intake of
lycopene. In their study, increases in serum lycopene across the
quartiles (lowest quartile ,38 mg/L to highest quartile .129 mg/
L) showed decreases in CVD risk [10]. The change in lycopene
levels seen in our intervention group (mean lycopene increase in
CVD active group 13068 mg/L) was greater than the inter-
quartile range seen in the observational study, suggesting that even
modest increases in serum lycopene may affect endothelial
function in atherosclerotic patients with endothelial dysfunction.
In a previous study by Kim et al. using a tomato extract which also
contained a mixture of other antioxidants, the 15 mg ‘lycopene
preparation’ increased serum lycopene levels by a mean of
130610 mg/L, which is almost the same as the increase seen in
our CVD arm at a dose of 7 mg using a lycopene-only preparation
[17]. However, it was unclear from that particular study which of
the antioxidants exerted the effects seen due to the mixed nature of
the active intervention.
Lycopene enhances endothelial function in CVD patients
independently of ‘traditional’ risk factors (BP, LDL) or systemic
inflammation. Little is known about how a ‘direct antioxidant’
effect may improve endothelial function. One hypothesis is that a
reduction in reactive oxygen species would increase the bioavail-
ability of NO and potentially decrease DNA and protein damage
[45]. Unfortunately, urinary isoprostane levels were below the
lower detection limit of our assay for the majority of the samples,
and there was wide variation in plasma nitrotyrosine levels, so we
were unable to confirm this effect in this study. Although tomato-
based dietary studies suggested improvements in oxidative stress
in-vivo [13,17,19], the antioxidant mechanism of action for
lycopene is controversial, with some authors suggesting that at
the concentrations found in the body, this mechanism is unlikely to
be significant [46]. Studies using other antioxidants suggest that
structural modifications of the compound due to metabolic
transformations in-vivo may profoundly affect bioactivity and
mechanisms of action [47]. Other putative ‘antioxidants’ have
shown beneficial effects on atherosclerosis without effects on
markers of oxidative stress so further work to determine the exact
mechanism of action of lycopene is needed [48].
Several limitations of the study are worth highlighting. The
study was designed as a proof-of-concept study investigating
mechanistic actions of lycopene using forearm plethysmography.
The study was powered on the primary endpoint of forearm
responses to ACh, which may explain why L-NMMA responses
did not reach statistical significance in the CVD arm and similarly
why other biomarker data was negative in a cohort with optimally
controlled risk factors. Lind et al. [26] showed that baseline
endothelium dependent responses to ACh correlate independently
with the risks of future CVD events. Drugs which improve CVD
mortality such as statins, b-blockers, ACE-inhibitors, and angio-
tensin receptor blockers have all shown beneficial effects on
endothelial function as measured by forearm responses to ACh
[31,49–51], but no study has demonstrated that the reversal of
endothelial dysfunction with an active intervention also alters
CVD mortality in the same individuals. These mechanistic results
must therefore be confirmed with subsequent interventional
clinical outcome studies.
The choice of lycopene dose was limited by the availability of
different dose regimens so we are unable to be definitive if a higher
Table 4. Post-hoc comparisons of baseline values between CVD Patients and HV arms.
CVD Patients [Mean Value (SD)] HVs [Mean Value (SD)] P-value*
Arterial Stiffness
Aortic PWV – m/s 9.0 (2.9) 7.9 (1.6) 0.05
AIx – % 32.2 (7.0) 27.3 (10.2) 0.02
Blood Pressure
Home SBP – mmHg 126 (12) 121 (13) 0.1
Home DBP – mmHg 76 (10) 72 (8) 0.1
Home SBP variability 9.0 (2.9) 8.2 (2.8) 0.3
Clinic SBP – mmHg 137 (12) 127 (16) 0.003
Clinic DBP – mmHg 81 (8) 77 (9) 0.04
Central SBP – mmHg 129 (12) 118 (17) 0.002
Central DBP – mmHg 81 (8) 77 (9) 0.04
Laboratory Markers
Lycopene – mg/L 140 (76) 174 (94) 0.1
LDL – mmol/L 2.4 (0.7) 3.6 (0.9) ,0.001
HDL – mmol/L 1.3 (0.4) 1.6 (0.5) 0.004
hsCRP – mg/L 1.90 (2.26) 1.73 (2.60) 0.8
ox-LDL – U/L 33.8 (77.8) 48.7 (117.7) ,0.001
Data are presented as mean values (standard deviation - SD). *P-value is for comparison between cardiovascular disease (CVD) patients arm and healthy volunteer (HV)
arm at baseline using unpaired, 2-tailed Student t-tests. AIx – augmentation index; DBP – diastolic blood pressure; HDL – high-density lipoprotein; hsCRP – high
sensitivity C-reactive protein; LDL – low-density lipoprotein; ox-LDL – oxidised low-density lipoprotein, PWV – pulse wave velocity; SBP – systolic blood pressure.
doi:10.1371/journal.pone.0099070.t004
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dose of lycopene may have altered endothelial responses in HVs.
The bioavailability of lycopene varies according to the preparation
of tomatoes (puree, ketchup etc.), as well as its origin, size, shape,
and the manner in which it is consumed (very bioavailable in the
presence of oil, for instance). Studies consistently highlight the
benefits of a diet high in fruits and vegetables for the secondary
prevention of CVD, with more recent studies suggesting a role for
olive oil consumed in conjunction with tomato products in
primary prevention in patients with CVD risk factors [3–5].
Supplementing one component of this diet may not necessarily
replace the benefits of a complex mixture of interacting nutrients
as part of a healthy diet. However, our study does provide
mechanistic evidence for the benefits of one such component of a
Mediterranean diet in CVD patients.
Conclusions
We have demonstrated, in a double blind, randomised,
controlled mechanistic trial, that lycopene improves endothelial
function in CVD patients who demonstrated impaired function at
baseline, despite optimal secondary prevention medication, but
not in age-matched, HVs. Our translational, in-vivo, physiological
study provides a mechanistic explanation for the beneficial effects
of lycopene, a component of the Mediterranean diet on the
vasculature. It reinforces the need for a healthy diet to augment
endothelial function in at-risk populations despite optimal medical
therapies. Most importantly, further interventional studies are
warranted to determine if lycopene supplementation could alter
cardiovascular outcomes in at-risk populations.
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